128 related articles for article (PubMed ID: 10371074)
1. Activated protein C resistance in young African American patients with ischemic stroke.
Chaturvedi S; Joshi N; Dzieczkowski J
J Neurol Sci; 1999 Mar; 163(2):137-9. PubMed ID: 10371074
[TBL] [Abstract][Full Text] [Related]
2. Factor V leiden and ischemic stroke risk: the Genetics of Early Onset Stroke (GEOS) study.
Hamedani AG; Cole JW; Cheng Y; Sparks MJ; O'Connell JR; Stine OC; Wozniak MA; Stern BJ; Mitchell BD; Kittner SJ
J Stroke Cerebrovasc Dis; 2013 May; 22(4):419-23. PubMed ID: 22100829
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Lindqvist PG; Svensson P; Dahlbäck B
J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Maryamchik E; Rosenbaum MW; Van Cott EM
Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Younis JS; Brenner B; Ohel G; Tal J; Lanir N; Ben-Ami M
Am J Reprod Immunol; 2000 Jan; 43(1):31-5. PubMed ID: 10698038
[TBL] [Abstract][Full Text] [Related]
6. Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Maryamchik E; Van Cott EM
Arch Pathol Lab Med; 2020 Nov; 144(11):1401-1407. PubMed ID: 32101451
[TBL] [Abstract][Full Text] [Related]
7. [Prevalence of the activated protein C resistance in indigenous and Black populations of the western Venezuela].
Vizcaíno G; Torres E; Quintero J; Herrmann F; Grimm R; Diez-Ewald M; Arteaga-Vizcaíno M; Pérez-Requejo JL; Colina-Araujo J
Invest Clin; 2000 Mar; 41(1):29-36. PubMed ID: 10758697
[TBL] [Abstract][Full Text] [Related]
8. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
10. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
Loew A; Jacob D; Neuhaus P; Riess H
Transplantation; 2005 May; 79(10):1422-7. PubMed ID: 15912114
[TBL] [Abstract][Full Text] [Related]
11. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.
Limdi NA; Beasley TM; Allison DB; Rivers CA; Acton RT
Blood Cells Mol Dis; 2006; 37(2):100-6. PubMed ID: 16889993
[TBL] [Abstract][Full Text] [Related]
12. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke.
Duran R; Biner B; Demir M; Celtik C; Karasalihoğlu S
Clin Appl Thromb Hemost; 2005 Jan; 11(1):83-8. PubMed ID: 15678277
[TBL] [Abstract][Full Text] [Related]
13. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
14. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years.
Lalouschek W; Schillinger M; Hsieh K; Endler G; Tentschert S; Lang W; Cheng S; Mannhalter C
Stroke; 2005 Jul; 36(7):1405-9. PubMed ID: 15947254
[TBL] [Abstract][Full Text] [Related]
15. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
16. A genetic study of Factor V Leiden (G1691A) mutation in young ischemic strokes with large vessel disease in a South Indian population.
Anadure R; Christopher R; Nagaraja D; Narayanan C
J Clin Neurosci; 2017 Oct; 44():346-352. PubMed ID: 28711293
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of factor V Leiden mutation testing in clinical practice.
Blinkenberg EØ; Kristoffersen AH; Sandberg S; Steen VM; Houge G
Eur J Hum Genet; 2010 Aug; 18(8):862-6. PubMed ID: 20332812
[TBL] [Abstract][Full Text] [Related]
18. Ischaemic stroke patients with heterozygous factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease.
Haapaniemi E; Helenius J; Jakovljević D; Soinne L; Syrjälä M; Kaste M; Lassila R; Tatlisumak T
Thromb Haemost; 2009 Jan; 101(1):145-50. PubMed ID: 19132201
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
Xin-Guang C; Yong-Qiang Z; Shu-Jie W; Lian-Kai F; Hua-Cong C
Clin Appl Thromb Hemost; 2015 Jul; 21(5):480-3. PubMed ID: 24335247
[TBL] [Abstract][Full Text] [Related]
20. Factor V Leiden as a common genetic risk factor for venous thromboembolism.
Horne MK; McCloskey DJ
J Nurs Scholarsh; 2006; 38(1):19-25. PubMed ID: 16579319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
